SKINVIVE by JUVEDERM
Allergan · Decision date Jun 11, 2026
What did the FDA approve?
FDA records P110033/S099 as a supplement to PMA P110033, with the supplement type “Panel Track”. The recorded decision is approval, dated Jun 11, 2026.
FDA approval order statement
SKINVIVE by JUVÉDERM is indicated for intradermal injection to improve skin smoothness of the cheeks and intradermal and/or subdermal injection to reduce neck lines for improvement of neck appearance in adults over the age of 21
- Regulatory pathway
- PMA supplement
- Supplement type
- Panel Track
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Jun 11, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P110033/S099
- Regulatory pathway
- PMA supplement
- Applicant
- Allergan
- Product code
- LMH
- Decision code
- APPR
- Decision date
- Jun 11, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implant, dermal, for aesthetic use.
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P110033/S099 received
Application receipt date recorded by FDA.
P110033/S101 · Related supplement
Juvéderm Voluma XC, Juvéderm Vollure XC, Juvéderm Volbella XC, Juvéderm Volux XC and SKINVIVE by Juvéderm (hereafter ref
P110033/S099 · FDA decision
Panel Track
P110033/S091 · Related supplement
Juvéderm Voluma XC, Vollure XC, Volbella XC, Volux XC, Skinvive
P110033/S102 · Related supplement
Juvéderm Voluma XC, Juvéderm Vollure XC, Juvéderm Volbella XC, Juvéderm Volux XC and SKINVIVE by Juvéderm
Timeline entries are records held by MedtechLedger for P110033. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P110033
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Allergan | PMA supplement | Aug 14, 2025 | FDA | |
| Allergan | PMA supplement | Aug 11, 2026 | FDA | |
| Allergan | PMA supplement | Aug 28, 2026 | FDA |
Explore the linked device profile
Other records with product code LMH
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Juvéderm Ultra XC; Juvéderm Ultra Plus XCP050047/S106 | Allergan | PMA supplement | Nov 4, 2026 | FDA |
Belotero Volume (+) LidocaineP250020/S004 | Merz North America, Inc. | PMA supplement | Nov 4, 2026 | FDA |
Belotero Intense (+) Lidocaine Dermal FillerP250016/S006 | Merz North America, Inc. | PMA supplement | Oct 21, 2026 | FDA |
| Prollenium Medical Technologies, Inc. | PMA supplement | Oct 14, 2026 | FDA | |
saypha ChiQP250021/S002 | Croma-Pharma GmbH | PMA supplement | Oct 8, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Allergan
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 2525 Dupont Dr., Irvine, CA, 92612
Sources and methodology
- Original FDA record: P110033/S099
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




